Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advertisement
Emily MenendezMuscle Invasive Urothelial Carcinoma | May 5, 2024
New findings from the Nure-Combo trial examined the use of ABX with nivolumab followed by RC and adjuvant nivolumab.
Read More
Zachary BessetteMuscle Invasive Urothelial Carcinoma | May 3, 2024
RT to recurrence sites may not have an effect on oncologic outcomes in patients with MIBC after RC.
Zachary BessetteMuscle Invasive Urothelial Carcinoma | May 3, 2024
Identifying tumor biomarkers associated with pCR to neoadjuvant pembro or NAC prior to cystectomy in patients with MIBC.
Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | April 25, 2024
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Katy MarshallMuscle Invasive Urothelial Carcinoma | April 8, 2024
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Katy MarshallMuscle Invasive Urothelial Carcinoma | March 27, 2024
Researchers analyzed the effects of NAC on complete and overall response as well as cancer-specific survival after RT.
Katy MarshallMuscle Invasive Urothelial Carcinoma | March 15, 2024
Patients received 68Ga-FAP-2286 PET, and investigators recorded the SUVmax of 68Ga-FAP-2286 PET-positive lesions.
Katy MarshallMuscle Invasive Urothelial Carcinoma | March 1, 2024
Data from 458 patients who underwent RC between October 2005 and October 2020 and 146 in the PURE-01 trial was analyzed.
Daniel M. Geynisman, MDASCO GU Symposium 2024 | January 30, 2024
Dr. Geynisman highlights the CheckMate 274 study into long-term survival following treatment with adjuvant nivolumab.
Tanya JindalASCO GU Symposium 2024 | February 1, 2024
Tanya Jindal discusses the safety and efficacy of neoadjuvant atezolizumab prior to radical cystectomy for MIBC.
Guru P. Sonpavde, MDASCO GU Symposium 2024 | February 4, 2024
Dr. Sonpavde provides a detailed overview of 2 of the bladder cancer trials of note: AMBASSADOR and PemCab.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | February 5, 2024
In patients with high-risk resected UC, adjuvant pembro is associated with improvement in disease-free survival.
Emily MenendezASCO GU Symposium 2024 | January 27, 2024
Patients with MIBC who are ineligible for cisplatin-based chemotherapy have no current standard of care options.
Brad McGregor, MDASCO GU Symposium 2024 | January 26, 2024
Drs. McGregor and Wallis continue their discussion by pivoting to the BLASST-1 trial.
Zachary BessetteASCO GU Symposium 2024 | February 1, 2024
Adjuvant pembrolizumab demonstrates improvement in DFS for patients with high-risk MIUC after radical surgery.
Katy MarshallASCO GU Symposium 2024 | January 29, 2024
Investigators used mixture cure models to estimate patients' underlying cure fraction after radical resection.
Zachary BessetteASCO GU Symposium 2024 | March 11, 2024
Researchers performed an exploratory biomarker analysis using different definitions of ctDNA response in the ABACUS trial.
Roger Li, MDMuscle Invasive Urothelial Carcinoma | January 22, 2024
Dr. Li highlights the EFS data and interesting findings among patients with residual disease in the bladder or lymph nodes.
Roger Li, MDMuscle Invasive Urothelial Carcinoma | January 22, 2024
Dr. Li describes his recent study comparing neoadjuvant pembro vs chemo or upfront cystectomy in patients with MIBC.
David Ambinder, MDUrothelial Carcinoma | January 16, 2024
Approximately 40 clinical trials related to bladder cancer were published at the end of 2022 and throughout 2023.
Advertisement
Advertisement
Advertisement